Home › Companies › CRINETICS PHARMACEUTICALS INC. › 2023-2024

CRINETICS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and CRINETICS PHARMACEUTICALS INC.’s Form 8-K, filed 2024-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
246Asset managers
1,495Fund votes
2024-06-07Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CRINETICS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by CRINETICS PHARMACEUTICALS INC.

These tallies are CRINETICS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CRINETICS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-06-07
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Camille Bedrosian, M.D.	50,829,173	--	--	14,947,321	2,328,910	Majority: yes
Elect Director: Wendell Wierenga, Ph.D.	50,300,772	--	--	15,475,722	2,328,910	Majority: yes

Source: CRINETICS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-06-10 — read the filing on EDGAR.

How asset managers voted at the CRINETICS PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 246 asset managers that disclosed a CRINETICS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of CRINETICS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission; and

SECTION 14A SAY-ON-PAY VOTES

Combines 13 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 240 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 97.8%AGAINST: 2.2%ABSTAIN: 0.0%NOT VOTED: 0.0%UNKNOWN: 0.0%

Largest asset managers voting on “To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
T. Rowe Price	11,153,375	0	For
Fidelity	9,988,348	0	For
State Street	4,784,234	34,568	For
BlackRock	4,327,372	12,267	For
DRIEHAUS CAPITAL MANAGEMENT LLC	3,820,421	0	For
Vanguard	3,580,103	0	For
Point72	2,789,934	0	For
JENNISON ASSOCIATES LLC	2,596,968	5,054	For
Wellington	2,192,157	0	For
Paradigm Biocapital Advisors LP	2,140,458	0	For
EcoR1 Capital, LLC	2,012,517	0	For
Prudential/PGIM	1,813,659	21,416	For
First Light Asset Management, LLC	1,631,938	0	For
Janus Henderson	1,610,539	2,972	For
GEODE CAPITAL MANAGEMENT, LLC	1,400,846	0	For
ORBIMED ADVISORS LLC	1,280,800	0	For
Cormorant Asset Management, LP	1,217,632	0	For
Novo Holdings A/S	1,098,600	0	For
PERCEPTIVE ADVISORS LLC	1,000,012	0	For
Charles Schwab	962,852	0	For
Ensign Peak Advisors, Inc	858,828	0	For
Bridge Builder Trust	811,987	23,401	For
LORD, ABBETT & CO. LLC	790,403	0	For
JANUS INVESTMENT FUND	718,929	0	For
DRIEHAUS MUTUAL FUNDS	614,365	0	For

Showing the 25 largest of 240 asset managers. See all 240 in the interactive database.

2. To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Camille Bedrosian, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 50,829,173WITHHELD: 14,947,321

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Camille Bedrosian, M.D.”): 50,829,173 for, 14,947,321 withheld, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,539,000 outstanding shares: 65% for, 19% withheld (84% of the company cast a for/withheld vote).

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (24,727,122 for, 128 against).

FOR 85%ABSTAIN 15%

FOR: 24,727,122 (85.1%)AGAINST: 128 (0.0%)ABSTAIN: 4,324,565 (14.9%)

Largest asset managers voting on “To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meet” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Fidelity	5,530,165	0	For
T. Rowe Price	4,733,729	0	For
Vanguard	3,467,622	0	For
BlackRock	2,356,253	0	For
Prudential/PGIM	1,693,762	124,143	For
State Street	1,757,917	25,749	For
MUTUAL FUND SERIES TRUST	1,059,633	0	For
Bridge Builder Trust	24,659	810,729	Abstain
JANUS INVESTMENT FUND	574,422	144,507	For
DRIEHAUS MUTUAL FUNDS	0	614,365	Abstain
Lord Abbett	0	585,764	Abstain
Charles Schwab	481,426	0	For
Dimensional	0	450,780	Abstain
TIAA	440,232	0	For
Hartford	403,084	0	For
Brinker Capital Destinations Trust	2,238	269,041	Abstain
JPMorgan	248,704	0	For
John Hancock	217,964	24,073	For
Equitable	192,375	31,268	For
Victory Capital	1,240	208,597	Abstain
Goldman Sachs	0	173,991	Abstain
First Trust	0	168,294	Abstain
FRANKLIN STRATEGIC SERIES	130,922	0	For
Invesco	129,569	0	For
Brighthouse	99,722	28,389	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

3. To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meeting of stockholders: Wendell Wierenga, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 50,300,772WITHHELD: 15,475,722

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 50,300,772 for, 15,475,722 withheld, per its Form 8-K filed 2024-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 78,539,000 outstanding shares: 64% for, 20% withheld (84% of the company cast a for/withheld vote).

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (24,462,565 for, 128 against).

FOR 84%ABSTAIN 16%

FOR: 24,462,565 (84.2%)AGAINST: 128 (0.0%)ABSTAIN: 4,589,122 (15.8%)

Largest asset managers voting on “To elect two directors to serve as Class III directors for a three-year term to expire at the 2027 annual meet” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Fidelity	5,530,165	0	For
T. Rowe Price	4,733,729	0	For
Vanguard	3,467,622	0	For
BlackRock	2,356,253	0	For
Prudential/PGIM	1,693,762	124,143	For
State Street	1,757,917	25,749	For
MUTUAL FUND SERIES TRUST	1,059,633	0	For
Bridge Builder Trust	24,659	810,729	Abstain
JANUS INVESTMENT FUND	574,422	144,507	For
DRIEHAUS MUTUAL FUNDS	0	614,365	Abstain
Lord Abbett	0	585,764	Abstain
Charles Schwab	481,426	0	For
Dimensional	0	450,780	Abstain
TIAA	440,232	0	For
Hartford	403,084	0	For
Brinker Capital Destinations Trust	2,238	269,041	Abstain
JPMorgan	248,704	0	For
John Hancock	217,964	24,073	For
Equitable	126,105	97,538	For
Victory Capital	1,240	208,597	Abstain
Goldman Sachs	0	173,991	Abstain
First Trust	0	168,294	Abstain
FRANKLIN STRATEGIC SERIES	130,922	0	For
Invesco	0	129,569	Abstain
Brighthouse	99,722	28,389	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

4. To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

AUDIT-RELATED

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 86 asset managers below cast 99.9% of the shares they voted on this item FOR (29,048,580 for, 3,235 against).

FOR: 29,048,580 (100.0%)AGAINST: 3,235 (0.0%)

Largest asset managers voting on “To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered pub” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
Fidelity	5,530,165	0	For
T. Rowe Price	4,733,729	0	For
Vanguard	3,467,622	0	For
BlackRock	2,356,253	0	For
Prudential/PGIM	1,817,905	0	For
State Street	1,780,625	3,041	For
MUTUAL FUND SERIES TRUST	1,059,633	0	For
Bridge Builder Trust	835,388	0	For
JANUS INVESTMENT FUND	718,929	0	For
DRIEHAUS MUTUAL FUNDS	614,365	0	For
Lord Abbett	585,764	0	For
Charles Schwab	481,426	0	For
Dimensional	450,780	0	For
TIAA	440,232	0	For
Hartford	403,084	0	For
Brinker Capital Destinations Trust	271,279	0	For
JPMorgan	248,704	0	For
John Hancock	242,037	0	For
Equitable	223,643	0	For
Victory Capital	209,837	0	For
Goldman Sachs	173,991	0	For
First Trust	168,294	0	For
FRANKLIN STRATEGIC SERIES	130,922	0	For
Invesco	129,569	0	For
Brighthouse	128,111	0	For

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

97% fund support · no official result

FOR 97%

The 3 asset managers below cast 97% of the shares they voted on this item FOR (991,684 for, 25,962 against).

FOR: 991,684 (97.4%)AGAINST: 25,962 (2.6%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at CRINETICS PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	594,037	0	For
JPMorgan	397,647	0	For
Desjardins Global Asset Management Inc.	0	25,962	Against

Largest CRINETICS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of CRINETICS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 78,539,000 shares outstanding at the time of that meeting.

Top CRINETICS PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	T. Rowe Price	14.20%
2	Fidelity	12.72%
3	State Street	6.14%
4	BlackRock	5.53%
5	DRIEHAUS CAPITAL MANAGEMENT LLC	4.86%
6	Vanguard	4.56%
7	Point72	3.55%
8	JENNISON ASSOCIATES LLC	3.31%
9	Wellington	2.79%
10	Paradigm Biocapital Advisors LP	2.73%

Reported CRINETICS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

CRINETICS PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	18.06%	13F
Vanguard Group	11.68%	13F
BlackRock	9.66%	13F
Point72	6.30%	13F
T. Rowe Price	4.87%	13F
State Street	4.14%	13F
Wellington Management	3.78%	13F
Perceptive Advisors LLC	1.90%	13D
Geode Capital	1.78%	13F
JPMorgan Chase	1.60%	13F

Percentages above are of 78,539,000 shares outstanding, as reported by CRINETICS PHARMACEUTICALS INC. on its Form 10-Q dated 2024-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CRINETICS PHARMACEUTICALS INC.’s 10-Q dated 2024-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At CRINETICS PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-07, in the 2023-2024 proxy season, 246 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,495 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. CRINETICS PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To consider and vote upon, on an advisory basis, the compensation of the Company's named… — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

CRINETICS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.